Cornerstone Therapeutics today upped its revenue projections for the year from$95 million to $104 million.
The increase takes into account two new products recently acquired by the Cary-based pharmaceutical company: the antibiotic Factive and Curosurf, which is used to treat a lung ailment that afflicts premature infants.
"We are excited about the potential these products have in the hands of our sales force, and expect them to be strong long-term contributors to our success," CEO Craig Collard said in a prepared statement.
Cornerstone also announced today that it posted a loss of $538,000, or three cents a share, in the third quarter.
Cornerstone was created last year when Cary's Cornerstone BioPharma acquired a Boston biotechnology company, Critical Therapeutics.